GeneCentric Therapeutics

GeneCentric Therapeutics is a Durham, North Carolina precision-oncology company that reads cancer's gene activity, not just its mutations, from a tube of blood. Its proprietary EXpressCT technology infers RNA-based gene expression signatures from cell-free DNA fragmentomics, and its GenomicsNext platform combines that expression read-out with DNA variant detection in a single liquid biopsy. The company also markets PurIST, an RNA expression subtyping test for pancreatic cancer. Founded in 2011 out of gene-expression research at UNC, GeneCentric partners with biopharma and commercial labs to bring richer, blood-based biomarkers into routine cancer care.